Pharmaceutical corporations are facing significant
“pressure points” as blockbuster drug launches continue
to slow and a number of major patents are due to expire
over the next several years, increasingly driving
restructuring and downsizing across the industry.
Indeed, high prices on new and existing drugs have
become a “double-edge sword” with pharma companies
needing more money to fund R&D innovation and payers
implementing formularies and other incentives to limit
drug use and curtail costs in response.
To help pharma companies adapt to the growing demand for
cost effectiveness, Thomas Nagle, a Monitor Group
partner and specialist in strategic pricing, prescribes
three value-based pricing models designed to boost the
health of pharma industry while protecting the
“well-being of the healthcare systems and the patients
it serves.” pdf 2008
